However, it was additionally reported as an agonist that recruited β-arrestin-2 to CXCR7 and was shown to block the transendothelial migration of CXCR4+/CXCR7+ human cancer cells, a similar result seen with CXCL11 [77]. Here, ACKR3 is linked to cancer.